Cargando…

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braunlin, Elizabeth A., Harmatz, Paul R., Scarpa, Maurizio, Furlanetto, Beatriz, Kampmann, Christoph, Loehr, James P., Ponder, Katherine P., Roberts, William C., Rosenfeld, Howard M., Giugliani, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228957/ https://www.ncbi.nlm.nih.gov/pubmed/21744090 http://dx.doi.org/10.1007/s10545-011-9359-8

Ejemplares similares

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Editorial: Cardiac issues in adults with mucopolysaccharidosis
por: Stepien, Karolina M., et al.
Publicado: (2022)

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013)

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Assessing the impact of the five senses on quality of life in mucopolysaccharidoses
por: Giugliani, Roberto, et al.
Publicado: (2020)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2022)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
por: Giugliani, Roberto, et al.
Publicado: (2021)

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
por: Hendriksz, Christian J., et al.
Publicado: (2014)

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management
por: Solanki, Guirish A., et al.
Publicado: (2013)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
por: Zanetti, Alessandra, et al.
Publicado: (2019)

Growth patterns in patients with mucopolysaccharidosis VII
por: Montaño, Adriana M., et al.
Publicado: (2023)

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels
por: Donida, Bruna, et al.
Publicado: (2017)

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
por: Harmatz, Paul, et al.
Publicado: (2010)

The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy
por: Wiesinger, Anna-Maria, et al.
Publicado: (2022)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients
por: Leiro, Beth, et al.
Publicado: (2021)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017)

International Guidelines for the Management and Treatment of Morquio A Syndrome
por: Hendriksz, Christian J, et al.
Publicado: (2015)

Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report
por: Ribeiro, Erlane Marques, et al.
Publicado: (2014)

Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders
por: Hendriksz, Christian J., et al.
Publicado: (2018)

An Uncommon Presentation of Mucopolysaccharidosis Type IIIb
por: REZAYI, Alireza, et al.
Publicado: (2019)

Atypical presentation of mucopolysaccharidosis type IVA
por: Rush, Eric T.
Publicado: (2016)

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
por: Hendriksz, Christian J., et al.
Publicado: (2012)

Pregnancy in patients with mucopolysaccharidosis: a case series
por: Stewart, Fiona J., et al.
Publicado: (2016)

Ocular features in mucopolysaccharidosis: diagnosis and treatment
por: Del Longo, Alessandra, et al.
Publicado: (2018)

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
por: Sawamoto, Kazuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2189ifgr5sabp6mgfvvhgg5nf6